Analyst Doug Loe of Echelon Wealth Partners is more cautious about Centric Health (TSX:CHH) after its second quarter financials, announced on Tuesday, … [Read more...] about “Disappointing” Centric Health is still a buy, says Echelon Wealth Partners
Analysts
Profound Medical Corp. has a potential game-changer on its hands, Paradigm Capital says
Investors may be disappointed with Profound Medical Corp’s (TSX:PRN) second quarter results, but Paradigm Capital analyst Rahul Sarugaser insists that … [Read more...] about Profound Medical Corp. has a potential game-changer on its hands, Paradigm Capital says
AcuityAds gets new $1.75 target at Haywood
Following the company's second quarter results, Haywood analyst Pardeep Sangha has raised his price target on AcuityAds (TSXV:AT). On Tuesday, … [Read more...] about AcuityAds gets new $1.75 target at Haywood
Promis Neurosciences has 79 per cent upside, says Mackie Research
After publishing its second quarter results, Canadian biotech company Promis Neurosciences (TSX:PMN) got a target price reduction from André Uddin of … [Read more...] about Promis Neurosciences has 79 per cent upside, says Mackie Research
Viemed Healthcare has 83 per cent upside, Beacon Securities says
Medical equipment supply company Viemed Healthcare (TSX:VMD) posted revenue and EBITDA beats in its second quarter financials, an indication of the … [Read more...] about Viemed Healthcare has 83 per cent upside, Beacon Securities says
Take a pass on Absolute Software: Paradigm Capital
Absolute Software’s (TSX:ABT) fiscal fourth quarter posted revenue in-line with expectations along with a consensus beat on EBITDA, an overall … [Read more...] about Take a pass on Absolute Software: Paradigm Capital
Cargojet gets new $94.00 target at Beacon Securities
Following the company's second quarter results, Beacon Securities analyst Ahmad Shaath has raised his price target on Cargojet (TSX:CJT). On … [Read more...] about Cargojet gets new $94.00 target at Beacon Securities
Quisitive Technology has 329 per cent upside, Echelon Wealth says
Microsoft Partner company Quisitive Technology Solutions (TSXV:QUIS) is a junior tech that can give investors exposure to a real blockchain … [Read more...] about Quisitive Technology has 329 per cent upside, Echelon Wealth says
Acerus Pharma has huge upside, Mackie Research says
Analyst André Uddin of Mackie Research Capital says the market dynamics in the United States for testosterone replacement therapy are favourable to … [Read more...] about Acerus Pharma has huge upside, Mackie Research says
Correvio is fully valued, says Mackie Research
Specialty pharmaceutical company Correvio Pharma (TSX, NASDAQ:CORV) is up 210 per cent year-to-date, but the run is over for the time being, says … [Read more...] about Correvio is fully valued, says Mackie Research